TuHURA Biosciences taps largest shareholder for $50M credit facility, draws $1.7M first tranche
What's the deal? TuHURA BiosciencesDealroom has a profile for this one. Try Dealroom → (NASDAQ: HURA), a Tampa-based pharmaceutical company, has secured a $50M revolving credit facility maturing in April 2031. The company drew an initial $1.7M on May 26, 2026, with funds earmarked for general corporate purposes including working capital and R&D.
The lender is an affiliate of TuHURA's largest stockholder — a detail that adds both strategic alignment and governance questions to the arrangement.
Why now? TuHURA, which trades on the Nasdaq Capital Market under the ticker HURA, appears to be shoring up its balance sheet for the long haul. The facility's 2031 maturity eliminates near-term refinancing risk and gives the company runway to advance its pharmaceutical development programmes or pursue acquisitions.
The company — previously known as Kintara Therapeutics, DelMar PharmaceuticalsDealroom has a profile for this one. Try Dealroom →, and Berry Only Inc. — has undergone multiple reinventions. This credit line signals a push to stabilise and scale under its current identity.
What could go wrong? Several risks stand out. Future drawdowns depend on meeting ongoing compliance requirements, and there's no guarantee TuHURA will be able to access the full $50M. If it can't, it may need to raise additional capital through other channels.
The related-party nature of the deal is the bigger concern. When a company's largest shareholder is also its lender, conflicts of interest can arise around governance, loan terms, and strategic decision-making. Investors should watch for how TuHURA handles these disclosures going forward.
The signal: TuHURA's pivot to personalised cancer vaccines — developing treatments designed to enhance immunotherapy effectiveness — places it in one of oncology's most competitive and capital-intensive segments. At the early growth stage, the company's decision to secure a $50M credit line from its largest shareholder rather than pursue public market fundraising suggests either limited appetite from institutional investors or a desire to avoid dilution at a depressed valuation. Either way, the arrangement underscores how thinly capitalised biotech firms increasingly rely on concentrated, related-party financing to fund long development timelines.
Read more: minichart.com.sg
